Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression
NCT ID: NCT01131559
Last Updated: 2014-03-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
50 participants
INTERVENTIONAL
2010-01-31
2014-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of Lisdexamfetamine to Treat Bipolar Depression
NCT01093963
Magnetic Resonance Imaging Study of Lisdexamfetamine for Bipolar Depression
NCT01051440
Ceftriaxone in the Management of Bipolar Depression
NCT00566111
ALTO-100 in Bipolar Disorder With Depression (BD-D)
NCT06656416
Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression
NCT00771134
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lisdexamfetamine
Drug
Lisdexamfetamine
Oral; 20-70mg/day
Placebo
Drug
Placebo control
Oral; 20-70mg/day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lisdexamfetamine
Oral; 20-70mg/day
Placebo control
Oral; 20-70mg/day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Clinically unstable medical disease, including cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine or other systemic disease. Subjects should be biochemically euthyroid to enter the study.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shire
INDUSTRY
University of Cincinnati
OTHER
Lindner Center of HOPE
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lindner Center of HOPE
Mason, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Link to facility where study is conducted
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Adjunctive LDX in BP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.